In light of the limited therapeutic options currently available for NSCLC, the Axl/Gas6 system remains an attractive therapeutic target,29 and some small molecules with Axl inhibitory effects are already under development.30 Elucidation of the exact mechanisms of Gas6 stimulation on tumor tissue (i.e., autocrine and/or paracrine) would increase the efficacy of targeting this RTK axis for the treatment of lung adenocarcinoma. Here, GAS6 is linked to neoplasm.